title: Upshaw-Schulman syndrome revisited: a concept of congenital thrombotic thrombocytopenic purpura.
abstract: Upshaw-Schulman syndrome (USS) is a congenital bleeding disorder characterized by repeated episodes of thrombocytopenia and microangiopathic hemolytic anemia that respond to infusions of fresh frozen plasma. Inheritance of USS has been thought to be autosomal recessive, because 2 siblings in the same family are often affected but their parents are asymptomatic. Recently, chronic relapsing thrombotic thrombocytopenic purpura (CR-TTP), reported almost exclusively in adults, was shown to be caused by inherited or acquired deficiency in the activity of a plasma von Willebrand factor-cleaving protease (vWF-CPase). The pathogenesis of USS is unknown, and a relationship between CR-YEP and USS has not been reported. We studied 3 unrelated USS patients (ST, SY, and KI) who presented with severe indirect neonatal hyperbilirubinemia. All 3 patients had undetectable vWF-CPase activity, and the inhibitors to vWF-CPase were all negative. In their parents with no clinical symptoms, vWF-CPase activities as a percentage of control samples (mother/father) were 17/20 for ST, 60/45 for SY, and 36/5.6 for KI. Thus, USS and vWF-CPase activity appear to be coinherited as autosomal recessive traits. Transfusion of fresh frozen plasma in 2 patients (ST and SY) resulted in the expected maximal increment of approximately 7% to 8% in vWF-CPase activity at 1 to 4 hours, but the levels became less than 3% within 2 days. After this decrease, platelet counts increased, plateaued in the normal range at 10 to 12 days, and declined thereafter. Thus, the 2 to 3 weeks of therapeutic benefit from plasma infusions will be discussed in relation to the intravascular lifetime of vWF-CPase.
authors.affiliation: Department of Pediatrics, Nara Medical University, Kashihara City, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Kinoshita
authors.forename: A
authors.initials: A
authors.lastname: Yoshioka
authors.forename: Y D
authors.initials: YD
authors.lastname: Park
authors.forename: H
authors.initials: H
authors.lastname: Ishizashi
authors.forename: M
authors.initials: M
authors.lastname: Konno
authors.forename: M
authors.initials: M
authors.lastname: Funato
authors.forename: T
authors.initials: T
authors.lastname: Matsui
authors.forename: K
authors.initials: K
authors.lastname: Titani
authors.forename: H
authors.initials: H
authors.lastname: Yagi
authors.forename: M
authors.initials: M
authors.lastname: Matsumoto
authors.forename: Y
authors.initials: Y
authors.lastname: Fujimura
mesh_terms: D051722:ADAM Proteins; D000071120:ADAMTS13 Protein; D000328:Adult; D000743:Anemia, Hemolytic / Q000201:enzymology / Q000235:genetics*; D005260:Female; D005808:Genes, Recessive; D006474:Hemorrhagic Disorders / Q000201:enzymology / Q000235:genetics* / Q000628:therapy; D006801:Humans; D007231:Infant, Newborn; D007564:Japan; D007567:Jaundice, Neonatal / Q000209:etiology* / Q000628:therapy; D008297:Male; D008666:Metalloendopeptidases / Q000172:deficiency* / Q000235:genetics; D010375:Pedigree; D010949:Plasma; D011697:Purpura, Thrombotic Thrombocytopenic / Q000145:classification / Q000151:congenital* / Q000201:enzymology / Q000235:genetics; D013577:Syndrome; D013921:Thrombocytopenia / Q000151:congenital* / Q000201:enzymology / Q000235:genetics / Q000628:therapy
chemical_list: D051722:ADAM Proteins; D008666:Metalloendopeptidases; D000071120:ADAMTS13 Protein; C099604:ADAMTS13 protein, human